Table 30Risk of fracture for calcium, relative to placebo, by fracture group*

Author, yearStudy durationType of fractureRisk levelNumber of fractures, calciumNumber of fractures, placebo or control†Odds ratio (95% CI)
ALL FRACTURES
Campbell, 200492 60 monthsNew symptomatic vertebral and non-vertebral fracturesIntermediate7/857/95†1.13 (0.38, 3.35)
Prince, 2006206**60 monthsAny site fractureHigh110/728126/7280.85 (0.64, 1.12)
Prince, 2006206***60 monthsAny site fractureHigh43/42263/4090.63 (0.42, 0.94)
Grant, 200565 62 monthsNew fracturesHigh189/1311196/13320.98 (0.79, 1.21)
VERTEBRAL FRACTURES
Campbell, 200492 60 monthsNew symptomatic or semi-quantittive vertebral fracturesIntermediate15/8519/95†0.86 (0.41, 1.81)
Grant, 200565 62 monthsClinical vertebral fractureHigh3/13111/13322.77 (0.39, 19.65)
Prince, 2006206**60 monthsVertebral deformityHigh44/43150/4500.91 (0.59, 1.40)
Prince, 2006206***60 monthsVertebral deformityHigh22/30632/3050.66 (0.38, 1.16)
Reid, 2006207 60 monthsVertebral fractureIntermediate27/73938/7320.70 (0.42, 1.14)
NON-VERTEBRAL
Prince, 2006206**60 monthsAny appedicular site fractureHigh83/72894/7290.87 (0.64, 1.19)
Prince, 2006206***60 monthsAny appredicular site fractureHigh39/41958/4110.63 (0.41, 0.96)
HIP
Grant, 200565 62 monthsProximal femur fractureHigh49/131141/13321.22 (0.80, 1.86)
Prince, 2006206**60 monthsProximal femurHigh11/7336/7501.86 (071, 4.83)
Prince, 2006206***60 monthsProximal femurHigh5/4173/4291.70 (0.42, 6.85)
Reid, 2006207 60 monthship fracture17/7395/7323.0 (1.29, 6.95)
WRIST
Grant, 200565 62 monthsDistal forearm fractureHigh33/131128/13321.20 (0.72, 2.00)
Prince, 2006206**60 monthsWrist or handHigh21/72420/7411.08 (0.58, 2.00)
Prince, 2006206***60 monthsWrist or handHigh10/41712/4140.82 (0.35, 1.92)
Reid, 2006207 60 monthsDistal forearm fractureIntermediate28/73944/7320.62 (0.39, 1.00)
*

High-risk: 1) transplant population, or 2) study entry criteria require T score ≤-2.5, or 3) study entry criteria require≥1 fracture, or 4) ≥ 50% population has 1 or more fractures at baseline or 5) Significant neuromuscular impairment. Intermediate-risk: 1) study entry criteria require T score ≤1.5, or 2) 10–50% of population has one or more fracture at baseline, or 3) study population has chronic disease that is commonly treated with glucocorticoids or 4) in the absence of data on BMD or fractures, mean age of population > 62 years. Low-risk: 1) study entry criteria require T score ≤0.0, or 2) < 10% of population has BMD =8 g/cm2 at baseline, or 3) 0–10% of population has one or more fracture at baseline, or in the absence of data on BMD or fracture, mean age of population <62 years. Unknown risk: BMD, fracture history and age not reported as entry criteria or in baseline characteristics of population.

**

Intention to treat analysis.

***

Compliant with medication.

Control group.

From: 3, Results

Cover of Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis
Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis [Internet].
Comparative Effectiveness Reviews, No. 12.
MacLean C, Alexander A, Carter J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.